Fulcrum Therapeutics, Inc. FULC

Fulcrum Therapeutics allocates 95% of the combined company to Slate and PIPE investors while distributing a $270M dividend. Majority ownership transfer to new investors plus large dividend signals transformative dilution and capital restructuring.

Fulcrum Therapeutics, Inc. (FULC) signs merger agreement with Slate Medicines. Merger agreement constitutes major strategic move likely to significantly alter company trajectory and investor sentiment.

Fulcrum Therapeutics, Inc. signs merger agreement with Slate Medicines. Merger agreement with Slate Medicines constitutes major strategic move altering Fulcrum trajectory.

Fulcrum Therapeutics merges with Slate Medicines to develop next-generation migraine therapies. Merger represents major strategic move into migraine therapies with potential to significantly shift company trajectory.

Fulcrum Therapeutics merges with Slate in $245M migraine biotech deal. Merger with Slate for $245M marks major strategic move into migraine treatments with potential to alter company trajectory.

Fulcrum Therapeutics merges with Slate Medicines in an all-stock deal. All-stock merger with Slate Medicines forms major strategic move altering Fulcrum's trajectory and market position.

Fulcrum Therapeutics merges with Slate Medicines to advance next-generation migraine therapies. Merger agreement drives major strategic shift into migraine treatment development.

Fulcrum Therapeutics, Inc. (FULC) will combine with Slate in a reverse merger. Reverse merger forms a major strategic move that can significantly alter Fulcrum's trajectory and investor sentiment.

Fulcrum Therapeutics (FULC) stock fair value decreases after company exits Pociredir program. Pociredir exit directly lowers Fulcrum fair value and signals pipeline contraction.

Fulcrum Therapeutics lost FDA approval for its only drug, triggering layoffs of 85% of staff despite holding hundreds of millions in cash. FDA rejection of the sole drug forced 85% staff cuts and eliminated the company's core pipeline.

Fulcrum Therapeutics scrapped its lead sickle cell drug and restructured operations, prompting reassessment of company valuation. Scrapping lead drug and restructuring signal major pipeline and operational setbacks.

Fulcrum Therapeutics ends sole drug program over cancer risk, triggering immediate stock crash. Loss of only pipeline asset eliminates future revenue and forces company pivot or shutdown.

Fulcrum Therapeutics stock plunged 48% after its sickle cell drug was deemed to have no viable path forward. Sickle cell drug failure removes the company's main pipeline asset and forces strategic reset.

Fulcrum Therapeutics explores potential sale after FDA sidelines its sickle cell drug. FDA sidelining of core sickle cell drug triggers sale exploration and indicates major strategic shift with substantial trajectory impact.

Fulcrum Therapeutics stock plunged nearly 50% after hours after FDA halted the company's sole clinical program over cancer risk. Loss of only clinical program removes Fulcrum's entire development pipeline and triggers immediate 50% stock collapse.

Fulcrum Therapeutics discontinues its sickle cell disease program after the US FDA raises malignancy concerns. Discontinuation of sickle cell program over FDA malignancy concerns severely damages pipeline and future prospects.

Fulcrum Therapeutics discontinues its Pociredir program in sickle cell disease and launches a strategic review. Discontinuation of the core Pociredir program and launch of strategic review will force major shifts in pipeline, operations, and valuation.

Fulcrum Therapeutics Inc (FULC) Q1 2026 earnings call highlights strategic advances amid challenges, covering pipeline progress, financial updates, and future outlook. Strategic advances in Q1 2026 earnings call represent major moves likely to alter Fulcrum Therapeutics' trajectory and investor sentiment.

Fulcrum Therapeutics, Inc. (FULC) released Q1 2026 earnings call summary detailing financial results, pipeline progress, operational updates, and forward guidance. Q1 2026 earnings summary highlights financials and pipeline advancements poised to significantly sway FULC's trajectory and investor sentiment.

Fulcrum Therapeutics (FULC) released its Q1 2026 earnings call transcript detailing financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses financial performance, pipeline progress, and strategic outlook impacting Fulcrum Therapeutics' trajectory.

Fulcrum Therapeutics released Q1 earnings call highlights covering financial results, pipeline progress, clinical updates, and strategic outlook. Q1 earnings highlights offer moderate updates on financials, pipeline, and operations influencing short-term market sentiment.

Fulcrum Therapeutics (FULC) shares climbed after Q1 earnings outperformed expectations. Q1 earnings beat drove share gains, positively influencing financial performance and market sentiment without fundamentally altering long-term trajectory.

Fulcrum Therapeutics, Inc. (FULC) announced recent business highlights and financial results for the first quarter of 2026. Quarterly financial results and business highlights affect key financial performance and investor sentiment.

Agios Pharmaceuticals shares rally on surprise FDA move advancing sickle cell treatment, pulling rival Fulcrum Therapeutics (FULC) stock higher in sympathy. FDA's surprise sickle cell move boosts Agios and lifts rival Fulcrum's stock, creating moderate positive sector sentiment without fundamentally altering Fulcrum's trajectory.

Fulcrum Therapeutics reports strong HbF increases and early vaso-occlusive crisis (VOC) signals from PIONEER study, outlines FDA regulatory pathway including potential accelerated approval. Positive Phase 1/2 PIONEER data with HbF gains, VOC signals, and accelerated approval discussions represent major clinical and regulatory progress for FULC.

Fulcrum Therapeutics, Inc. Q4 2025 earnings call summary covers financial results, pipeline updates, and strategic outlook for the biotech firm. Q4 2025 earnings call summary reveals financial performance, clinical progress, and guidance that could substantially shift investor sentiment and company trajectory.

Fulcrum Therapeutics announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Positive Phase 1b trial results for pociredir advance Fulcrum's sickle cell disease pipeline, likely boosting investor sentiment and stock performance.

Fulcrum Therapeutics released Q4 earnings call highlights covering financial results, pipeline updates, and strategic outlook. Q4 earnings highlights detail financials and pipeline progress with moderate influence on investor sentiment and trajectory.

Fulcrum Therapeutics announced recent business highlights and financial results for the fourth quarter and full year 2025. Q4 and full-year 2025 financial results alongside business highlights affect financial performance and market sentiment moderately.

Fulcrum Therapeutics to present 12-week data from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Phase 1b trial data presentation advances pociredir pipeline in sickle cell disease, likely influencing investor sentiment and stock performance moderately.